Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by pericles1on May 30, 2010 8:55pm
273 Views
Post# 17141982

RE: SCC of the lung Early Results

RE: SCC of the lung Early Results

It's the same pattern of the last couple years they put out an early article about an enrolled patient, I must admit two months is shorter than usual and they picked a decent result.  I learned a long time ago that one patient can be very misleading two is a trend. They hype it to increase enrollment and then we don't hear about again for over a year, that's what has happened with the NSCLC trial.  The fact is that our trials are having trouble coming up with the patients against all the other trials. 

What the hell is going on with the confirmation results with Head and Neck. Actually the more Brad brags about multiple partnerships etc. the more nervous I become! I think Brad in the short term is anxious to get the stock into the 3 plus range before he nails us with the dilution. The strong oder of a stock offering is moving through the air, I think it could come in the next month or two, sooner than I expected.
Bullboard Posts